Neuropeptide Y Identified as a Key Link Between Cell Aging and Inflammation in Rheumatoid Arthritis

Collagen-induced arthritis was established in DBA/1 mice, followed by 40 days of rapamycin treatment. RNA sequencing and bioinformatic analyses identified differentially expressed genes and altered pathways. Results were validated by RT-qPCR and immunohistochemistry. Functional assays using NPY gene silencing in fibroblast-like synoviocytes (FLS) confirmed the peptide's role in regulating inflammatory and senescence pathways.

Rheumatoid arthritis affects about 1% of the global population, and current treatments focus on broadly suppressing the immune system. Identifying NPY as a molecular connector between cellular aging and joint inflammation opens a more targeted therapeutic avenue. If NPY or its receptors can be selectively modulated, it could address both the inflammatory and degenerative aspects of arthritis simultaneously — something current treatments don't achieve.

Cellular senescence has emerged as a major driver of age-related diseases, and the senescence-associated secretory phenotype (SASP) is increasingly recognized as a key source of chronic inflammation. This study adds NPY to the growing list of peptide mediators connecting senescence and inflammation, and positions it within the mTOR/rapamycin signaling network. The finding that NPY regulates sirtuins and autophagy genes connects it to fundamental aging biology, suggesting relevance beyond arthritis to other age-related inflammatory conditions.

This is a preclinical study using a collagen-induced arthritis mouse model, which doesn't fully replicate human RA. The in vitro NPY silencing experiments were performed in isolated synoviocytes, which may behave differently in the complex joint environment. The study did not test whether directly targeting NPY in vivo (rather than using rapamycin) would reduce arthritis severity. Rapamycin has broad effects, so the specific contribution of NPY modulation to the overall therapeutic effect is unclear.